This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Celgenes performance against key rivals in the prescription pharmaceutical sector
- Understand how Revlimid will drive the companys performance out to 2013
- See how the acquisition of Pharmion will affect Celgenes strategy
